(600529)"Shandong Pharmaceutical Glass Co., Ltd."Report for Q3 2026
Filed with SSE · Stock code 600529 · · 13 pages · Chinese
Summary by 6ix AI
The report includes a summary of major accounting data and financial indicators, as well as non-recurring gains and losses. The financial statements included are unaudited and cover the consolidated balance sheet, income statement, and cash flow statement.
Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries
Shandong Pharmaceutical Glass Co., Ltd. on 6ix
Earlier from Shandong Pharmaceutical Glass
- (600529)"Shandong Pharmaceutical Glass Co., Ltd."Announcement on Progress in Using Certain Idle Raised Funds to Purchase Structured Deposits
- (600529)"Shandong Pharmaceutical Glass Co., Ltd."Announcement on Redemption upon Maturity of Structured Deposits Purchased with Certain Idle Raised Funds
- (600529)"Shandong Pharmaceutical Glass Co., Ltd."Indicative Announcement on the Reply to the Review Inquiry Letter Regarding the Application Documents for the Private Placement of Shares and Updates of the Prospectus and Other Application Documents
- Announcement on Receipt of the Review Inquiry Letter from the Shanghai Stock Exchange Regarding the Company's Application for Private Placement of Shares
- Announcement on Change of Sponsor Representative
Later from Shandong Pharmaceutical Glass
- (600529)"Shandong Pharmaceutical Glass Co., Ltd."Announcement on Approval by the Shanghai Stock Exchange of the Application for the 2026 Private Placement of A-Shares
- (600529)"Shandong Pharmaceutical Glass Co., Ltd."Announcement on Progress of Redemption upon Maturity of Structured Deposits Purchased with Certain Idle Raised Funds and Continued Purchase of Structured Deposits
Follow Shandong Pharmaceutical Glass into a list and get an email when it puts out news.
Follow Shandong Pharmaceutical Glass